This is an aggregated industry headline. Read the full story at FierceBiotech →
cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara
In another biotech born out of China's "NewCo" model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
By FierceBiotech
· Jun 21, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Name recognition and "familiarity" with Novo Nordisk's oral Wegovy has contributed to its rapid uptake in its …
The WeekBriefing
With pharma M&A and IPOs accelerating, unprepared companies risk missing out as investors demand speed, clean …
The WeekAJMC ↗
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently…